About Sutro Biopharma
Sutro Biopharma is a company based in United States founded in 2003. Sutro Biopharma has raised $171.85 million across 11 funding rounds from investors including Merck, Citadel and Celgene. The company has 338 employees as of December 31, 2024. Sutro Biopharma offers products and services including XpressCF+ and iADCs. Sutro Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter United States
- Employees 338 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sutro Biopharma, Inc.
-
Annual Revenue
$62.04 M (USD)-59.64as on Dec 31, 2024
-
Net Profit
-$227.46 M (USD)-112.99as on Dec 31, 2024
-
EBITDA
-$231.24 M (USD)-180.41as on Dec 31, 2024
-
Total Equity Funding
$171.85 M (USD)
in 11 rounds
-
Latest Funding Round
$85.4 M (USD), Series E
Jul 26, 2018
-
Investors
Merck
& 13 more
-
Employee Count
338
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sutro Biopharma
Sutro Biopharma is a publicly listed company on the NASDAQ with ticker symbol STRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sutro Biopharma
Sutro Biopharma offers a comprehensive portfolio of products and services, including XpressCF+ and iADCs.
Cell-free technology for protein expression in drug development.
Antibody-drug conjugates for targeted cancer treatments.
People of Sutro Biopharma
Unlock access to complete
Unlock access to complete
Leadership Team
43 people
Software Development Team
22 people
Senior Team
14 people
Product Management Team
10 people
Clinical Team
8 people
Scientist Team
8 people
Operations Team
5 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Sutro Biopharma
Sutro Biopharma has successfully raised a total of $171.85M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $85.4 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sutro Biopharma
Sutro Biopharma has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Citadel and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Locked | Locked | Locked |
Investor details for Sutro Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sutro Biopharma
Investment portfolio details for Sutro Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sutro Biopharma
Detailed financials for Sutro Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sutro Biopharma Comparisons
Peer comparison for Sutro Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sutro Biopharma
Sutro Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Sutro Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sutro Biopharma
Complete news archive for Sutro Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sutro Biopharma
Sutro Biopharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Sutro Biopharma is headquartered in United States.
Sutro Biopharma is a funded company, having raised a total of $171.85M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Sutro Biopharma is 338.
Annual revenue of Sutro Biopharma is $62.04M as on Dec 31, 2024.
Sutro Biopharma was founded in 2003 in the United States within the biotechnology sector. Antibody-based therapeutics targeting cancer are developed using the XpressCF cell-free protein synthesis platform. Discoveries such as STRO-001 for B-cell malignancies and STRO-002 for ovarian and endometrial cancers have been enabled by this technology. Operations focus on advancing these treatments through research and development in oncology.
Sutro Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Sutro Biopharma offers XpressCF+ and iADCs.
Yes, Sutro Biopharma is publicly traded on NASDAQ under the ticker symbol STRO.
Sutro Biopharma has 14 investors. Key investors include Merck, Citadel, Celgene, Tekla Capital Management, and Samsara BioCapital.
The ticker symbol of Sutro Biopharma is STRO on NASDAQ.